Small molecule disease-modifying medicines
NRG is developing pipeline of brain-penetrant small molecule inhibitors of the mitochondrial permeability transition pore.
Source: drugtargetreview.com
📰 Biomedical Catalyst News
Page 3 - Biomedical Catalyst News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Biomedical Catalyst. Real-time updates on events, politics, business and more.
Mitochondria in focus as 4BIO Capital co-leads financing in LUCA Science
4BIO Capital has co-led Series B financing in LUCA Science Inc., which is developing a novel class of mitochondria biopharmaceutical agents.
Source: labiotech.eu
NRG receives £2.68m funding boost for neurodegenerative disorders
NRG Therapeutics announces multi-million Innovate UK Award to develop treatments for Parkinson’s and motor neurone disease - News - PharmaTimes
United Kingdom Arthur Roach Michaelj Fox Foundation Innovate United Kingdom Award Biomedical Catalyst Innovate United Kingdom
Source: pharmatimes.com
NRG Therapeutics developing new Parkinson's and MND treatments
UK neuroscience company NRG Therapeutics Ltd has received an award to fund preclinical development of its novel small molecule disease-modifying medicines for the treatment of Parkinson's disease, motor neuron disease (MND) and other chronic neurodegenerative disorders.
United Kingdom Neil Miller Arthur Roach Therapeutics Ltd Michaelj Fox Foundation Biomedical Catalyst
Source: labiotech.eu
NRG Therapeutics Announces £2.68M Innovate UK Award to Develop New Medicines to Treat Parkinson's and Motor Neuron Disease
NRG Therapeutics Ltd (“NRG” or “company”), an innovative neuroscience company targeting mitochondrial dysfunction, is pleased to announce that it has received a highly competitive Biomedical Catalyst (BMC) award to fund pre-clinical development of its novel small molecule disease-modifying medicines for the treatment of Parkinson's disease, motor neuron disease (MND) and other debilitating chronic neurodegenerative disorders.
Source: biospace.com
NRG Therapeutics Announces £2.68M Innovate UK Award to Develop New Medicines to Treat Parkinson's and Motor Neuron Disease
/PRNewswire/ -- NRG Therapeutics Ltd ("NRG" or "company"), an innovative neuroscience company targeting mitochondrial dysfunction, is pleased to announce that...
Source: prnewswire.com
STORM Therapeutics Awarded Innovate UK Grant to Discover and Develop a Novel Coronavirus Therapy Targeting an RNA-Modifying Enzyme
/PRNewswire/ -- STORM Therapeutics, the biotechnology company focused on the discovery of small molecule therapies targeting RNA epigenetic mechanisms, today...
Source: prnewswire.com
Invizius Awarded Second Biomedical Catalyst Grant to Research Peritoneal Dialysis Option for its H-Guard® Technology
/PRNewswire/ -- Invizius Limited ("Invizius"), a biotechnology company developing treatments to suppress unwanted immune responses in haemodialysis, today...
Glasgow City United Kingdom City Of Candy Herbert Prnewswire Invizius Limited University Of Edinburgh
Source: prnewswire.com
Invizius Awarded Second Biomedical Catalyst Grant to Research Peritoneal Dialysis Option for its H-Guard® Technology
/PRNewswire/ -- Invizius Limited ("Invizius"), a biotechnology company developing treatments to suppress unwanted immune responses in haemodialysis, today...
Glasgow City United Kingdom City Of Candy Herbert Prnewswire Invizius Limited University Of Edinburgh
Source: prnewswire.com
Invizius Awarded Major Biomedical Catalyst Grant to bring Anti-Inflammatory Haemodialysis Treatment to The Clinic
/PRNewswire/ -- Invizius Limited ("Invizius"), a biotechnology company developing treatments to suppress unwanted innate immune responses, today announces that...
Source: prnewswire.com